 |
|
|
| |
A Multivariate Analysis of the Phase 3 BRIGHTE Trial, Through Week 24, to Identify Predictors of Virologic Response to Fostemsavir in Heavily Treatment-Experienced People Living With HIV
|
| |
| |
HIV Drug Therapy Glasgow; October 23-26, 2022; Virtual and Glasgow, Scotland
Margaret Gartland,1 Xueqi Wang,1 Qiming Liao,1 Bo Li,2 Fangfang Du,2 Shiven Chabria,3 Mark Krystal,3 Andrew Clark,4 Max Lataillade,3 Allan Tenorio3
1ViiV Healthcare, Durham, NC, USA; 2GSK, Collegeville, PA, USA; 3ViiV Healthcare, Branford, CT, USA; 4ViiV Healthcare, Brentford, UK
|
| |
|
|
|
|
|
